Tag: SNDY

TLON, AONE & Extended Watchlist

Talon Therapeutics, Inc.TLON

It seems many folks are jumping on the TLON bandwagon after yesterday’s FDA approval announcement. We first began mentioning TLON on July 23rd, and have talked about it quite a bit since then.  At the time, 1.34 was the low. In the week following it managed a high of 1.83 for a 37% gain. On August first, the stock had cropped back to .81, only to turn around the next day and run to 1.27, for an added 57% gain.

Yesterday the range was .82 to 1.23, on over 7X its 3mo average volume. The announcement seems to have brought even more traders to the party than there were anticipating the announcement. Opportunity should continue to knock as word travels on TLON.

Be sure to tune into today’s conference call regarding all the latest TLON happenings:

Date: August 10, 2012
Time: 12:00pm EDT, 9:00am PDT
Dial-in (US and Canada):  (877) 681-1326 
Dial-in (International):  (708) 290-1158 
Webcast: www.talontx.com

____

A123 Systems, Inc. AONE

Yesterday AONE broke the previous session’s high, hitting a new high of .62, and closing at the 20DMA of .61.

We are looking for the momentum to continue, as the stock appears to be gapping up this morning. The next major patch of resistance should come at around .88.

The RSI is coming off of being oversold. The blue bars on the histogram just flipped up to the bullish side. We have a PPO that is pinching, and ready to cross over. The Slow STO did cross and is starting to head north toward the 50DMA.

____
Extended Watchlist:
BBDA, SNDY, AAPT, ICPA

Talon Therapeutics (TLON) FDA Approval & Other Updates

Talon Therapeutics, Inc. TLON

We are happy to report that TLON received its FDA stamp of approval today, and has been trading well as a result. A news release bearing the good news came across the wire this morning.

The high today was 1.23 after being as low as .86, for possible intraday gains of 43%

SOUTH SAN FRANCISCO, Calif., Aug 9, 2012 (GlobeNewswire via COMTEX) — Talon Therapeutics today announced Marqibo(R) (vinCRIStine sulfate LIPOSOME injection) received accelerated approval from the U.S. Food and Drug Administration (FDA) for the treatment of adult patients with Philadelphia chromosome negative (Ph-) acute lymphoblastic leukemia (ALL) in second or greater relapse or whose disease has progressed following two or more anti-leukemia therapies. This indication is based on overall response rate.

A conference call is slated to discuss this and other company developments is tomorrow:

Conference Call Information 

 Date: August 10, 2012 
Time: 12:00pm EDT 
Dial-in (US and Canada):  (877) 681-1326  
Dial-in (International):  (708) 290-1158   
Webcast: www.talontx.com

____

All American Pet Company, Inc. AAPT

A big-time performer off of this morning’s extended watchlist, AAPT has had a monster day thus far. After a close of .0129 yesterday, the daily range has been .015-.0224, for a total possible gain of 49.3%

We had this play in our watchlist originally beginning last week, giving our readers ample time to check out the stock. At the time, the low was .011, meaning anyone shrewd enough to jump on AAPT early this week, today enjoyed gains exceeding 100%

____

Extended Watchlist:
SNDY, RENU, EGCT